Suvaxyn Aujeszky 783 + O/W

RSS

live attenuated Aujeszky's disease virus

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 30/06/2017

Authorisation details

Product details
Name
Suvaxyn Aujeszky 783 + O/W
Agency product number
EMEA/V/C/000038
Active substance
live attenuated Aujeszky's disease virus
International non-proprietary name (INN) or common name
live attenuated Aujeszky's disease virus
Species
Pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AA01
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
07/08/1998
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

23/03/2017 Suvaxyn Aujeszky 783 + O/W - EMEA/V/C/000038 - IG/0747

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of pigs from the age of 10 weeks to prevent the mortality and clinical signs of Aujeszky's disease and to reduce the excretion of Aujeszky's disease field virus. Passive immunisation of the progeny of vaccinated gilts and sows to reduce mortality and clinical signs of Aujeszky's disease and to reduce the excretion of Aujeszky's disease field virus.

Assessment history

How useful was this page?

Add your rating